Investor Presentaiton

Investor Presentation First six months of 2018 Slide 23 Novo Nordisk has leading positions in diabetes, obesity and haemophilia Diabetes Market value Obesity Market value Haemophilia Market value DKK billion Novo Nordisk value market share DKK Global market position billion Novo Nordisk value market share Global market position DKK billion Novo Nordisk value market share Global market position #1 600 50% 10 #1 50% #2 80 50% 70 500 40% 8 40% 40% 60 400 30% 6 30% 50 30% 300 40 CAGR¹ value: 1.9% 20% 4 - 20% CAGR¹ value: 16.3% 30 20% 200 CAGR² value: 49.7% 20 10% 2 10% 10% 100 10 0% 0% 0% May 2013 May 2018 May 2016 May 2018 FY 2013 FY 2017 1 CAGR for 5-year period Source: IQVIA MAT May, 2018 value figures changing diabetes® Note: Value data is based on Australia, Belgium, Brazil, Canada, Chile, Denmark, Germany, Italy, Mexico, Russia, Spain, UAE, USA 2 CAGR for 2-year period Source: IQVIA MAT May, 2018 value figures Note: Annual sales figures for Haemophilia A, B and Bypassing agents segment. Recombinant and plasmal derived products Source: Company reports novo nordisk

View entire presentation